Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
JCO Oncology Practice · 2025-06 · 21 (6) · 747-753
DOI: 10.1200/op-24-00626 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-06. Verfasst von Neal Shore und 25 weiteren Autor:innen. Beteiligte Einrichtung: Carolina Urologic Research Center, Myrtle Beach, SC. Hauptthemen laut MEDLINE: Genetic Testing, Germ-Line Mutation, Prostatic Neoplasms, Standard of Care. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Carolina Urologic Research Center, Myrtle Beach, SC.
- Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA.
- University of Minnesota, Masonic Cancer Center, Minneapolis, MN.
- Case Western Reserve University, Cleveland, OH.
- The Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
- Exact Sciences Corporation, Madison, WI.
ORCID-Profile: Neal Shore, Sarah M Nielsen, Edward D Esplin, Emmanuel S Antonarakis, Pedro C Barata, Tomasz M Beer, Himisha Beltran, Alan Bryce, Tanya B Dorff, Daniel J George, Elisabeth I Heath, Brian T Helfand, Maha Hussain, Rana R Mckay, Alicia K Morgans, Michael J Morris, Ashley E Ross, Oliver Sartor, David R Wise, Andrew J Armstrong
Förderung
- NCI NIH HHS
Zitieren
APA
Shore, N., Nielsen, S. M., Esplin, E. D., Antonarakis, E. S., Barata, P. C., Beer, T. M., Beltran, H., Bryce, A., Cookson, M. S., Crawford, E. D., Dorff, T. B., George, D. J., Heath, E. I., Helfand, B. T., Hussain, M., Mckay, R. R., Morgans, A. K., Morris, M. J., Paller, C. J., …, & Armstrong, A. J. (2025). Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncology Practice, 21(6), 747-753. https://doi.org/10.1200/op-24-00626
Vancouver
Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, et al. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncology Practice. 2025;21(6):747-753. doi:10.1200/op-24-00626
BibTeX
@article{Shore2025,
author = {Shore, Neal and Nielsen, Sarah M and Esplin, Edward D and Antonarakis, Emmanuel S and Barata, Pedro C and Beer, Tomasz M and Beltran, Himisha and Bryce, Alan and Cookson, Michael S and Crawford, E David and Dorff, Tanya B and George, Daniel J and Heath, Elisabeth I and Helfand, Brian T and Hussain, Maha and Mckay, Rana R and Morgans, Alicia K and Morris, Michael J and Paller, Channing J and Ross, Ashley E and Sartor, Oliver and Shen, John and Sieber, Paul and Smith, Matthew R and Wise, David R and Armstrong, Andrew J},
title = {Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {6},
pages = {747--753},
doi = {10.1200/op-24-00626}
}
EUVIMED